Oct. 18, 2021– A new federal government report could add momentum to efforts on Capitol Hill to end limitations on 340B price discounts for orphan drugs purchased by certain safety-net hospitals. The report suggests that drug companies might be seeking orphan status for their products to maximize revenues and avoid paying 340B discounts on drugs widely used to treat common … [Read more...]
New Data May Convince Congress To Close 340B Loophole
March 18, 2021– One of the quieter debates around the 340B drug pricing program is percolating on Capitol Hill as lawmakers consider whether to plug a loophole in the law that costs rural hospitals much-needed resources. Members of Congress from both parties are looking to pass legislation to make a change on this issue. And a recent study in the prestigious journal Health … [Read more...]
Congress Urged to Loosen Limits on 340B Discounts for Orphan Drugs
June 29, 2020— A pair of researchers is calling on Congress to relax the limitations on 340B price discounts for orphan drugs at safety-net hospitals during the national response to the COVID-19 pandemic. In an opinion piece posted June 25 in Health Affairs, they note that many of the drugs being tested to treat or prevent COVID are considered orphan drugs – meaning they were … [Read more...]
Faces of 340B: The Sting of High Drug Prices
June 4, 2019— The connection between the 340B drug pricing program and scorpions might not be a natural one for an outsider to make. But the health professionals at Arizona-based Banner Health know how important the former can be for someone who has an unfortunate run-in with the latter. In the southwest U.S., patients experiencing stings from poisonous bark scorpions … [Read more...]
NPR and Kaiser Health News Explore 340B Orphan Drug Exclusion
September 18, 2017—National Public Radio and Kaiser Health News have collaborated on an in-depth report on how a federal law that denies rural hospitals 340B drug discounts on orphan drugs “has left rural hospital pharmacists and health care workers struggling to keep medicines in stock, and wondering if they will be able to adequately care for patients.” … [Read more...]